
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
The FDA's expanding embrace of new approach methodologies (NAMs) is forcing pharmaceutical manufacturing and quality teams to rethink how preclinical and CMC data will be generated, validated, and used. Richard Jaenisch, speaking with PharmTech associate editorial director Christopher Cole, lays out both the promise and the unresolved questions that come with it.






